We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.035 | 0.08% | 44.025 | 44.62 | 43.89 | 44.16 | 5,011,211 | 19:32:06 |
From May 2022 to May 2024
By Cecilia Butini
Evotec SE said Tuesday that it has expanded a partnership originally signed in 2016 with Bristol Myers Squibb Co. for the development of treatments for neurodegenerative diseases, which could potentially result in a deal of $4 billion.
The German biotechnology company said the extension is for eight years, and that it will receive an upfront payment of $50 million, plus license and performance milestone payments for an undisclosed sum, and tiered royalties up to low double-digit percentages on product sales.
"Including the upfront and downstream performance milestone payments, the overall transaction results in a deal potential of $4 billion," Evotec said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 28, 2023 06:12 ET (10:12 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
